Concentrations of interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), and soluble tum or necro sis factor receptor (sTNFR) p55 and p75 were measured in 25 patients with sepsis syndrome. Sequential blood samples were drawn from patients during a 7-h period. IL-6 concentrations were 34-763,000 pg/m L; they were higher in nonsurvivors than survivors, but the difference was not statistically significant. In septic patients, the median sIL-6R concentration was significantly lower than in 19 healthy volunteers (43 vs. 80 ng/mL). SÏL-6R concentrations in survivors were not significantly different than those in nonsurvivors. There was a negative correlation between IL-6 and sIL-6R in septic patients (r = -.72). In patients with moderately impaired renal func tion, SÏL-6R levels were not affected, but the concentrations of sTN FR s were significantly higher. 
IL-6 is particularly associated with disease severity and prog nosis. Recently, however, it has becom e evident that not only the cytokine but also circulating cytokine receptors and cytokine-cytokine receptor com plexes are involved in the effects o f cytokines in sepsis.
Several cytokines, including IL-6 [1] and T N F [2] , have circulating soluble receptors, which have a m odulating effect on their activity. For exam ple, binding o f T N F to its soluble receptor inhibits its biologic activity, thereby protecting the organism from the harm ful effects o f excessive T N F [2] .
However, low concentrations o f soluble T N F receptors (sT N F R s) can au g m en t the effects o f the cytokine by in creasing its half-life [3] . In contrast, the soluble IL-6 receptor (sIL-6R) seems to stim ulate the biologic activity o f IL-6. In the presence o f sIL-6R, the IL -6-stim ulated production o f acute-phase proteins in hepatic cell cultures is en h an ced [4] and IL -6 -d ep en d en t m yelom a cell lines show increased growth [5] .
sIL-6R is a 50-to 55-kD a ligand-binding protein that binds IL-6. It is the extracellular part o f the gp80 subunit from the m em brane-anchored IL-6 receptor. W hen IL-6 is bound to m em brane-anchored gp80, the com plex associates with a signal transducing subunit, gp 130, that generates a signal into the cell [6] .
In septic patients, levels o f circulating IL-6 correlate well with the severity o f disease an d patient m ortality [7] . Since sIL-6R may strongly m odulate the effects o f IL-6, we studied the circulating levels o f IL-6 and sIL-6R in a group o f septic patients. W e also determ ined both soluble T N F receptors (sT N FR s; p55 and p75) to com pare their patterns with those o f sIL-6R. Different patterns were expected because o f the assum ed differences in biologic function.
Materials and M ethods
Patients. Sixteen men and 9 women with a mean age of 58 years (range, 18-86) participated in the study. They were se lected from patients in the intensive care unit of the University Hospital Nijmegen. All study patients had sepsis syndrome ac cording to the criteria of Bone [8] . In brief, patients had clinical evidence of infection, tachycardia, fever or hypothermia, and tachypnea, accompanied by at least one of the following mani festations of inadequate organ function or perfusion: alteration of mental status, hypoxemia, metabolic acidosis, oliguria, or dis seminated intravascular coagulation. Exclusion criteria were the use of > 20 mg/day ofglucocorticosteroids and a creatinine clear ance of <10 mL/min.
Nineteen of the 25 patients were in shock, which was defined as a sustained decrease of systolic blood pressure to < 90 mm Hg or a drop of 40 mm Hg from baseline or the presence o f any vasopressors. APACHE II scores were calculated over the 24-h period before study inclusion (mean ± SD, 20.0 ± 5.6; range, 9-30). For calculation of the scores, the Glasgow coma score (15) was estimated to be normal because most patients were sedated at testing.
At study entry, 6 patients had bacteremia: Blood cultures re vealed gram-negative rods in 3 patients, gram-positive cocci in 1, and mixed flora in 2. The infectious diagnoses of the nonbacteremic patients included peritonitis (6), pneum onia (3), pye lonephritis (1), catheter-site infection (2) Patient samples. Starting 30 min before the first dose of anti biotic and then 0, 1,2, 4, and 6 h later, blood samples were drawn from each participant. Serum samples were allowed to clot at room temperature, and sera were collected after centrifu gation. Plasma was collected in 4-mL tubes (Vacutainer System; Becton Dickinson, Rutherford, NJ) containing 48 pL of 15% EDTA(K3) and 250 of aprotinin (Bayer, Leverkusen, Ger many). Sera and plasma were stored at -20°C until use.
Control samples. As controls, 1 blood sample was drawn from each of 19 healthy hospital employees. Data on age and sex were not collected.
IL-6 andsIL-ôR ELISA. IL-6 and sIL-6R ELISAs were used as described [6] . The detection ranges of the ELISAs were 20-800 pg/mL (IL-6 ) and 0.4-25.0 ng/mL (sIL-6R). Neither the addition of IL-6 to sIL-6R nor the addition of sIL-6R to IL-6 influenced the detection of the cytokine or its soluble receptor [6] . IL-6 and sIL-6R were determined in serum.
sTNFR p55 and p75 determinations. sTNFRs were deter mined in plasma using an enzyme-linked immunobinding assay provided by H. Gallati (Hoffmann-La Roche, Basel, Switzer land). Detection levels were 80 pg/mL for p55 and 300 pg/mL for p75. In healthy volunteers, normal values (median ± SD) are 1470 ± 190 pg/mL for p55 and 2520 ± 660 pg/mL for p75 [9] .
Statistical analysis. Spearman's correlation coefficients were used to calculate the relationship between IL-6 and sIL-6R levels and APACHE II scores. Differences between groups were tested using the Wilcoxon rank sum test: P < .05 was considered significant, two-tailed test.
Results
Over the 7-h study period, which began 30 min before administration of antibiotic, the mean coefficient of varia tion for sIL-6R and IL-6 in the septic patients was 16% and 36%, respectively; thus, there were only minor variations. Figure 1 shows the median values for each patient.
IL-6 concentrations were elevated in all patients (range, 34-736,000 pg/mL). Although not statistically significant (P = .4), median IL-6 concentrations in the nonsurvivor group (3060 pg/mL) were higher than in the survivor group (988 pg/mL). IL-6 concentrations in the healthy volunteers were all below the detection limit (<20 pg/mL) and statistically different from the patients (P < .0001).
The median level of circulating sIL-6R in the control group was 80 ng/mL (range, 46-1 15). In septic patients, however, sIL-6R levels were significantly reduced (median, 43 ne/mL; ranee, 10-165) compared with the healthy con trols (P = .0001).
There was a strong negative correlation between median levels of IL-6 and the accompanying sIL-6R in septic pa tients (r = -.72; P = .0001). The median levels of IL-6 for each patient correlate well with the APACHE II score (/• = .50; P = .01). For the median sIL-6R levels no significant correlation was found with the APACHE II score. When the IL-6:sIL-6R ratio was calculated and related to APACHE II scores, the Spearman correlation coefficient remained the same as for IL-6 alone (/* = .50, P = .01). sTNFR p55 and p75 concentrations were also determined in the septic patients. The mean coefficient of variation for sTNFR p55 and p75 were 8% and 10%, respectively, indicat- ing a stable concentration during the study period. sTNFR concentrations, determined in 23 patients, ranged from 2.4 to 30.9 ng/mL for p55 and from 5.4 to 75.8 ng/mL for p75. Neither receptor level differed significantly between survi vors and nonsurvivors during the study. There was no signifi cant correlation between sTNFRs and sIL-6R.
To investigate the role of renal function in maintaining soluble receptor levels, patients were divided into groups with normal (n = 18) or impaired (n -7) renal function (creatinine concentration range, 0.6-1.9 and 2.0-3.4 mg/ 100 mL, respectively). Median concentrations of sIL-6R in patients with normal renal function (43.3 ng/mL) did not significantly differ from patients with impaired renal func tion (43.0 ng/mL). However, sTNFR levels were signifi cantly higher in patients with impaired renal function (p55, 1 7.6 ng/mL; p75, 31.6 ng/mL) than in patients with normal renal function (p55, 6.4 ng/mL [P < .001 ]; p75, 11.7 ng/mL [ƒ>< .005]).
Discussion
The principal finding in this study was that patients with sepsis syndrome have decreased circulatory concentrations of sIL-6R with concomitantly high concentrations of IL-6. The concentrations of sIL-6R in normal volunteers were comparable to those previously described [1, 5] . Compared with the control group, septic patients in the current study had significantly lower concentrations of sIL-6R. These data contrast with the findings reported in HIV-seropositive pa tients and patients with monoclonal gammopathy, in whom levels of sIL-6R were elevated compared with controls [ 1, 5] . These diseases are obviously fundamentally different from sepsis, but increased IL-6 concentrations have been de scribed in patients with all three diseases [10, 11] . Appar ently, in HIV-seropositive patients and patients with mono clonal gammopathy, the relationship between IL-6 and sIL-6R is different from the one in sepsis; however, to our knowledge, a study measuring both IL-6 and sIL-6R in these patients has not been published.
How sIL-6R concentrations are regulated is not clear. Pos sibly the IL-6/sIL-6R complex is internalized by the effector cells, resulting in a decreased expression of gp80 on the cell surface [12] . Assuming that membrane-anchored IL-6R is the main source of sIL-6R, the increased turnover of mem brane-anchored IL-6R in the presence of high levels of IL-6 might be responsible for the decreased levels of sIL-6R.
It is known that sIL-6R is generated either by shedding of the membrane-anchored gp80 [13] or by direct production of an sIL-6R form through transcription of a specific mRNA [14] . How this production is regulated has not been deter mined. Protein kinase C (PKC) seems to play an important role in shedding. Inhibitors of PKC might have a down-regu lating effect on sIL-6R production. IL-6 seems to have no effect on shedding of the gp80 ligand-binding protein [13] .
Snyers and Content [15] showed that the expression of the gp 130 component of IL-6R is enhanced by IL-6. The expres sion of both components, however, may be regulated by dif ferent mechanisms.
Preliminary results of ex vivo whole blood assays suggest that circulating cells are probably not involved in the produc tion or use of sIL-6R. When LPS is added to whole blood, IL-6 is produced in large amounts (*$100,000 pg/mL). How ever, compared with concentrations in control blood sam ples, without the addition of LPS the concentration of sIL-6R does not change (unpublished data).
Other researchers have also found elevated levels of circu lating TNF receptors in patients with severe infections (e.g., sepsis, malaria, and meningococcemia). In our study group, both TNF and IL-6 were increased during sepsis, but the pattern of their soluble receptors is different and the concen trations were not correlated. These findings suggest a differ ent biologic role for both cytokine receptors: sTNFR may inhibit and sIL-6R enhances the biologic effects of TNFcx and IL-6, respectively.
It is well known that concentrations of sTNFRs in sepsis are influenced by renal function [16] . In this study, we con firm that septic patients with renal impairment have higher sTNFR concentrations. For sIL-6R, no relation with the cre atinine levels was found. This suggests that the renal clear ance of sIL-6R is not an important way to regulate levels. This idea is supported by the fact that only small amounts of sIL-6R are found in the urine of healthy humans compared with circulating concentrations [6] . However, because pa tients with a renal clearance of <10 mL/min were excluded from this study, no definitive conclusions can be drawn. Pre liminary results in patients with chronic hemodialysis indicate an increase in basal levels of sIL-6R. This means that moderate renal impairment influences sTNFR concentra tions but not sIL-6R concentrations.
In previous in vitro studies, the biologic effects of sIL-6R [4, 5] were different from the biologic effects of sTNFR [2] . Here we demonstrate that the in vivo pattern of sIL-6R in septic patients is also different from that of sTNFR. We can only speculate on the biologic significance of the reduction of sIL-6R during sepsis. It might be a way to decrease the biologic activity of IL-6 or just a result of internalization of IL-6 together with its receptor.
